{
    "clinical_study": {
        "@rank": "25027", 
        "acronym": "AQUATIC", 
        "arm_group": [
            {
                "arm_group_label": "Tolvaptan", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective is to evaluate the efficacy and safety on the tolvaptan for increasing serum\n      Na levels in patients with worsening heart failure and hyponatremia."
        }, 
        "brief_title": "Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure With Hyponatremia", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Hyponatremia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group\n      interventional study comparing tolvaptan (15 to 60 mg) to placebo in adult patients\n      hospitalized (or admission to emergency room) due to worsening of heart failure and\n      dilutional hyponatremia. All patients will be on standard therapy for heart failure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Patients hospitalized due to heart failure with clinically significant\n             hyponatremia (except hypovolemic) (defined as serum Na < 125 mEq/L or less marked\n             hyponatremia that is symptomatic and has resisted correction with fluid restriction\n             [Appendix 4]) prior to randomization.\n\n             2. Male and female patients aged \u2265 20 years. 3. Subject who diagnosed with heart\n             failure and New York Heart Association (NYHA) class III/\u2163.\n\n             4. Signs of extracellular volume expansion, defined as two or more of the following:\n             JVD, peripheral edema, dyspnea or pulmonary congestion.\n\n             5. B-type natriuretic peptide (BNP) \u2265 150 pg/mL or N terminal (NT)-proBNP \u2265 450\n             pg/mL.\n\n        Exclusion Criteria:\n\n          -  \"1. Women who are pregnant, breast feeding, or of childbearing potential who are not\n             using acceptable contraceptive methods (such as barrier contraceptives or methods\n             that result in a failure rate of less than 1%).\n\n             2. Patients with hyponatremia in hypovolemic states, defined as the presence of\n             clinical and historical evidence of extracellular fluid volume depletion, including\n             but not limited to skin turgor, orthostatic changes in blood pressure (BP) or heart\n             rate (HR), dry mucous membranes, or a response to i.v. saline challenge.\n\n             3. Patients unable to sense or respond to thirst. 4. Patients who are likely to\n             require prolonged hospitalization for reasons other than chronic heart failure (CHF),\n             e.g. new femoral fracture surgery requiring extended recovery.\n\n             5. Patients with recent prior treatment for hyponatremia, such as hypertonic saline\n             (within 8 h, just before the  administration) or urea, lithium or tolvaptan (within 4\n             days, just before the administration) .\n\n             6. Patients with severe hyponatremia symptoms requiring immediate intervention with\n             hypertonic saline; or who are expected to require such therapy within 48 h after\n             randomization.\n\n             7. Patients with causes of neurological symptoms, which are attributable to\n             psychological (psychoses), structural (dementia of the Alzheimer's type, post-infarct\n             dementia) or other metabolic causes (e.g. hyper- or hypo- oxemia, glycaemia,\n             calcemia, ammonemia, etc.) 8. Patients with acute and transient hyponatremia\n             associated with head trauma or severe neurological injury (e.g. stroke, subdural\n             hematoma).\n\n             9. Patients with a history of hyponatremia known to be due to severe, untreated\n             hypothyroidism/adrenal insufficiency.\n\n             10. Patients with psychogenic polydipsia. 11. Patients with systolic BP < 90 mmHg at\n             screening. Note, if it is confirmed under the BP<90mmHg at the first attempt, in\n             addition, conduct a test twice more. And if it fits two results out of three in the\n             criteria, the subject can be enrolled.\n\n             12. Patients with a history of hypersensitivity and/or idiosyncratic reaction to\n             benzazepine or benzazepine derivatives (such as benazepril), or tolvaptan.\n\n             13. Patients with a history of drug or medication abuse within the 3 months prior to\n             screening, or current alcohol abuse.\n\n             14. Patients with uncontrolled diabetes mellitus defined as glucose > 300 mg/dL (16.7\n             mmol/L) without regard to meals.\n\n             15. Patients with a current urinary tract obstruction (e.g. obstructive benign\n             prostatic hypertrophy).\n\n             16. Anuric patients. 17. Patients with a serum creatinine > 3.5 mg/dL at screening.\n             18. Terminally ill patients or patients with a moribund condition who have little\n             chance of short-term (e.g. 30 day) survival.\n\n             19. Patients whose hyponatremia is the result of any medication that cannot safely be\n             withdrawn, such as anti-convulsants (e.g. carbamazepine) and anti psychotics (e.g.\n             haloperidol).\n\n             20. Patients receiving desmopressin within 2 days of screening. 21. Patients who have\n             participated in another investigational drug trial within the past 30 days(except for\n             Non-interventional study).\n\n             22. Any patient who, in the opinion of the investigator, would not be able to comply\n             with the study drug administration or study procedures, or whose overall medical\n             condition would prohibit their participation in the study. (ex, severe pneumonia,\n             infectious disease and etc.) 23. Patients treated and/or to be treated with strong\n             cytochrome P450 (CYP) 3A inhibitors (clarithromycin, ketoconazole, itraconazole,\n             ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, telithromycin).\n\n             24. Patients with rare hereditary problems of galactose intolerance, Lapp lactase\n             deficiency or glucose- galactose malabsorption.\n\n             25.Patients with Aspartate transaminase(AST) or alanine transaminase(ALT) >2.5 times\n             the upper limit of normal(UNL), total bilirubin > 2mg/dL or who under any medication\n             treatment for liver disease at screening\""
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865214", 
            "org_study_id": "156-KOB-1201i"
        }, 
        "intervention": {
            "arm_group_label": "Tolvaptan", 
            "description": "to titrate upwards to 15mg to 60mg, once a daily", 
            "intervention_name": "Tolvaptan", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2013", 
        "location": {
            "contact": {
                "email": "djchoi@snubh.org", 
                "last_name": "Dong Ju Choi, Doctor", 
                "phone": "82-31-787-7007"
            }, 
            "facility": {
                "address": {
                    "city": "Seongnam-si", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "463-707"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia", 
        "overall_contact": {
            "email": "djchoi@snubh.org", 
            "last_name": "Dong Ju Choi, Doctor", 
            "phone": "82-31-787-7007"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Average daily AUC of change from baseline in serum Na level to day 4 within the double-blind treatment period", 
            "safety_issue": "No", 
            "time_frame": "from baseline to day 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865214"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Korea Otsuka International Asia Arab", 
        "sponsors": {
            "collaborator": {
                "agency": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Korea Otsuka International Asia Arab", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}